A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (NCT06697197)

🧪 Interventions in This Study

• BMS-986482 (DRUG)
• Nivolumab and rHuPH20 (DRUG)
• Nivolumab/relatlimab/rHuPH20 (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (21 Sites)

• University of California, Irvine (UCI) Health - UC Irvine Medical Center — Irvine, California
• The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
• Local Institution - 0008 — Aurora, Colorado
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
• Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Fred Hutchinson Cancer Center — Seattle, Washington
• UZ Gent — Ghent, Oost-Vlaanderen
• Rigshospitalet — Copenhagen, Capital Region
• Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone — Marseille, Bouches-du-Rhône
• Gustave Roussy — Villejuif, Paris
• General Hospital of Athens "Laiko" — Athens, Attikí
• Papageorgiou General Hospital of Thessaloniki — Thessaloniki, Thessaloníki
• Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy
• Istituto Clinico Humanitas — Rozzano, Milano
• Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) — Amsterdam, North Holland
• Erasmus Medisch Centrum — Rotterdam,
• Hospital Universitari Vall d'Hebron — Barcelona, Barcelona [Barcelona]
• Clinica Universidad de Navarra — Pamplona, Navarre
• Hospital Universitario HM Sanchinarro — Madrid,
• Karolinska Universitetssjukhuset Solna — Solna, Stockholms Län [se-01]

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors

• A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
• A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
• QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California

Explore by condition: All Advanced Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.